Cargando…

HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment

North America's first government sanctioned medically supervised injection facility (SIF) was opened during September 2003 in Vancouver, Canada. This was in response to a large open public drug scene, high rates of HIV and hepatitis C transmission, fatal drug overdoses, and poor health outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Tyndall, Mark W, Wood, Evan, Zhang, Ruth, Lai, Calvin, Montaner, Julio SG, Kerr, Thomas
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766348/
https://www.ncbi.nlm.nih.gov/pubmed/17176481
http://dx.doi.org/10.1186/1477-7517-3-36
_version_ 1782131658200186880
author Tyndall, Mark W
Wood, Evan
Zhang, Ruth
Lai, Calvin
Montaner, Julio SG
Kerr, Thomas
author_facet Tyndall, Mark W
Wood, Evan
Zhang, Ruth
Lai, Calvin
Montaner, Julio SG
Kerr, Thomas
author_sort Tyndall, Mark W
collection PubMed
description North America's first government sanctioned medically supervised injection facility (SIF) was opened during September 2003 in Vancouver, Canada. This was in response to a large open public drug scene, high rates of HIV and hepatitis C transmission, fatal drug overdoses, and poor health outcomes among the city's injection drug users. Between December 2003 and April 2005, a representative sample of 1,035 SIF participants were enrolled in a prospective cohort that required completing an interviewer-administered questionnaire and providing a blood sample for HIV testing. HIV infection was detected in 170/1007 (17%) participants and was associated with Aboriginal ethnicity (adjusted Odds Ratio [aOR], 2.70, 95% Confidence Interval [95% CI], 1.84–3.97), a history of borrowing used needles/syringes (aOR, 2.0, 95% CI, 1.37–2.93), previous incarceration (aOR, 1.87, 95% CI, 1.11–3.14), and daily injection cocaine use (aOR, 1.42, 95% CI, 1.00–2.03). The SIF has attracted a large number of marginalized injection drug users and presents an excellent opportunity to enhance HIV prevention through education, the provision of sterile injecting equipment, and a supervised environment to self-inject. In addition, the SIF is an important point of contact for HIV positive individuals who may not be participating in HIV care and treatment.
format Text
id pubmed-1766348
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-17663482007-01-11 HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment Tyndall, Mark W Wood, Evan Zhang, Ruth Lai, Calvin Montaner, Julio SG Kerr, Thomas Harm Reduct J Research North America's first government sanctioned medically supervised injection facility (SIF) was opened during September 2003 in Vancouver, Canada. This was in response to a large open public drug scene, high rates of HIV and hepatitis C transmission, fatal drug overdoses, and poor health outcomes among the city's injection drug users. Between December 2003 and April 2005, a representative sample of 1,035 SIF participants were enrolled in a prospective cohort that required completing an interviewer-administered questionnaire and providing a blood sample for HIV testing. HIV infection was detected in 170/1007 (17%) participants and was associated with Aboriginal ethnicity (adjusted Odds Ratio [aOR], 2.70, 95% Confidence Interval [95% CI], 1.84–3.97), a history of borrowing used needles/syringes (aOR, 2.0, 95% CI, 1.37–2.93), previous incarceration (aOR, 1.87, 95% CI, 1.11–3.14), and daily injection cocaine use (aOR, 1.42, 95% CI, 1.00–2.03). The SIF has attracted a large number of marginalized injection drug users and presents an excellent opportunity to enhance HIV prevention through education, the provision of sterile injecting equipment, and a supervised environment to self-inject. In addition, the SIF is an important point of contact for HIV positive individuals who may not be participating in HIV care and treatment. BioMed Central 2006-12-18 /pmc/articles/PMC1766348/ /pubmed/17176481 http://dx.doi.org/10.1186/1477-7517-3-36 Text en Copyright © 2006 Tyndall et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Tyndall, Mark W
Wood, Evan
Zhang, Ruth
Lai, Calvin
Montaner, Julio SG
Kerr, Thomas
HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment
title HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment
title_full HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment
title_fullStr HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment
title_full_unstemmed HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment
title_short HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment
title_sort hiv seroprevalence among participants at a supervised injection facility in vancouver, canada: implications for prevention, care and treatment
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766348/
https://www.ncbi.nlm.nih.gov/pubmed/17176481
http://dx.doi.org/10.1186/1477-7517-3-36
work_keys_str_mv AT tyndallmarkw hivseroprevalenceamongparticipantsatasupervisedinjectionfacilityinvancouvercanadaimplicationsforpreventioncareandtreatment
AT woodevan hivseroprevalenceamongparticipantsatasupervisedinjectionfacilityinvancouvercanadaimplicationsforpreventioncareandtreatment
AT zhangruth hivseroprevalenceamongparticipantsatasupervisedinjectionfacilityinvancouvercanadaimplicationsforpreventioncareandtreatment
AT laicalvin hivseroprevalenceamongparticipantsatasupervisedinjectionfacilityinvancouvercanadaimplicationsforpreventioncareandtreatment
AT montanerjuliosg hivseroprevalenceamongparticipantsatasupervisedinjectionfacilityinvancouvercanadaimplicationsforpreventioncareandtreatment
AT kerrthomas hivseroprevalenceamongparticipantsatasupervisedinjectionfacilityinvancouvercanadaimplicationsforpreventioncareandtreatment